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Introduction
Myasthenia gravis (MG) is an autoimmune disease due to 
the production of autoantibodies binding to acetylcholine 
receptors or other related molecules at the neuromuscular 
junction, thereby causing muscle weakness. The etiologies 
of MG are only partially understood, which includes 
genetic risk factors and thymic pathologies (1). Neoplastic, 
inflammatory and age-related thymus are likely involved in 
the immunopathogenesis of MG (2). 
Thymectomy has become an indispensable treatment for 
patients with MG. From a historical perspective, surgical 
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therapy for MG actually developed earlier than medications. 
In 1912, Schumacher and Roth first reported a 18-year-old 
woman with hyperthyroidism and MG who experienced 
improvement of myasthenia after a subtotal thyroidectomy 
through an incision in the neck (3). About two decades 
later in 1939, Blalock described a durable remission of MG 
after transsternal thymectomy (4). Later in 1941, Blalock 
further reported encouraging early results of six patients 
with MG after transsternal thymectomy and recommended 
a complete removal of all thymus tissue to alter the course of 
MG due to the presence of thymic abnormalities in patients 
with MG (5). Thereafter, median sternotomy became a 
widespread approach for thymectomy in the majority of 
thoracic surgery clinics except for several institutes where 
transcervical approach for thymectomy was preferred (6,7), 
which opened up the discussion on radicality of thymectomy. 
Although ectopic foci of the thymic tissue was first described 
in 1912 by Wenglowski (8), it was not until in 1975 that 
Masaoka found high incidence of extracapsular thymic tissue 
in mediastinal fat, concluding that an extended resection 
with thymus and all mediastinal fat is necessary for patients 
with MG (9). Since then, many retrospective studies have 
been conducted to compare extended with limited resections 
in patients with MG, concluding that the more complete 
resection, the higher the remission rate (10,11). Recently, 
the Myasthenia Gravis Thymectomy Trail (MGTX) 
first determined the therapeutic value of thymectomy in 
nonthymomatous MG (12,13). However, it is common 
knowledge that even total thymectomy does not result in 
complete stable remission in all patients. This might be 
partly due to ectopic tissue that is surgically inaccessible 
even through an aggressive approach (14). Removal of the 
residual thymus by reoperation can relieve the persistent 
symptoms after “partial” resections (15-20). Furthermore, 
ectopic thymic tissue was found in more than a half of the 
specimens after reoperations (20). Thus, ectopic thymic 
tissue seems to play an important role in patients with MG. 
It is of importance to have a thorough knowledge 
of ectopic thymic tissue in patients with MG, thereby 
providing researchers and surgeons better chance to deal 
with it and improve the quality of care. Recently, Marx 
and colleagues have conducted a comprehensive review 
on ectopic thymic tissue and ectopic thymic tumors (21). 
Hereby, we aimed at providing an overview on the specific 
role of ectopic thymic tissue in MG patients focusing on the 
definition and identification, the prevalence and distribution 
and the clinical significance. 
Materials and methods
A systematic search of the literature was performed on 
PubMed and Medline in September 2018 using iterations 
of the phrases to locate any studies reporting ectopic thymic 
tissue in patients with MG with or without thymoma. The 
systematic review was developed according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISM) statement (22). The review did not register at any 
website and a review protocol did not exist.
“(((ectopic thymic tissue) OR heterotopic thymic tissue)) 
AND ((((myasthenia gravis[Title/Abstract]) OR myasthenic 
syndrome[Title/Abstract]) OR neuromuscular disease[Title/
Abstract]) OR neuromuscular junction disease[Title/
Abstract])”.
Fifty-nine studies were found and assessed for inclusion. 
The reference lists of the relevant studies were also searched 
for additional studies. At last, we included 18 studies that 
reported the rate of ectopic thymic tissue in patients with 
MG and summarized in Table 1.
Results
Definition and identification
Thymus is usually composed of multiple lobes, separately 
encapsulated, and anatomically located in the anterior 
superior mediastinum. Ectopic thymic tissue is frequently 
defined as the un-encapsulated lobules of thymus or 
microscopic foci of thymic tissue that are located outside 
the normal position, widely distributing in the mediastinal 
fat between the level of the thyroid and the diaphragm 
(9,14,23,37). Recently, the role of “active ectopic thymic 
tissue” was introduced and defined as the presence of 
germinal center in the ectopic thymic tissue (37).
Several imaging techniques have been researched on the 
detection of ectopic thymic tissue preoperatively (40-43). 
Ectopic thymus can be visualized by ultrasound, computed 
tomography (CT) and magnetic resonance imaging (MRI) 
(40-42). However, their diagnostic role in detecting widely 
distributed ectopic thymic tissue in mediastinal fat is still 
lacking. Standardized uptake value (SUV) of perithymic 
region on positron emission tomography (PET) was 
reported to be correlated with the discovery of ectopic 
thymic tissue after thymectomy (43). Although it could 
be greatly helpful to locate possible ectopic thymic tissue 
preoperatively, data on the diagnostic accuracy of imaging 
techniques in ectopic thymic tissue imaging are still lacking. 
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In pathological studies (24,32,33,37), specimens were 
usually dissected and labeled by anatomical locations. Tissue 
fragments were embedded in paraffin block after fixed in 
10% formalin. Then, tissue blocks were sliced and stained 
using hematoxylin and eosin. Ectopic thymic tissue was 
searched usually in 1 from every 5 tissue sections of fatty 
tissue. The diagnosis of ectopic thymic tissue was confirmed 
by the presence of the Hassals corpuscles. Moreover, in one 
study, Ambrogi and Mineo also used monoclonal antibodies 
against CD23 to assess the presence of the germinal centers, 
thereby demonstrating the presence of active ectopic thymic 
tissue (37).
Prevalence and distribution
Table 1 summarizes the prevalence and common locations of 
ectopic thymic tissue in patients with MG. The median rate 
of ectopic thymic tissue in patients with MG is 41% (range, 
26–98%) according to previous retrospective studies (Table 1). 
The range of the reported rate is quite wide, possibly due 
to different surgical procedures, methods of the histological 
investigation and the intensities of the workup. Ten out of 
18 studies reported the common locations of ectopic thymic 
tissue in mediastinal fat (24,25,29,30,32-37). Of these ten 
studies, 882 patients were studied on ectopic thymic tissue 
in different anatomical locations, of whom 509 patients 
(58%) were positive. Unfortunately, the studied anatomical 
locations varied from one to another. The authors 
summarized and calculated the rates of ectopic thymic 
tissue in several commonly reported anatomical regions 
(Figure 1): anterior mediastinal perithymic fat 293 (33.2%), 
pericardiophrenic angles 120 (13.6%), aortopulmonary 
window 92 (10.4%), cervical region (pretracheal fat): 66 
(7.5%), lateral to phrenic nerves 34 (3.9%), aortocaval 
groove 14 (1.6%), behind innominate vein 6 (0.7%). It is 
worth mentioning that the authors categorized anterior 
mediastinal fat and perithymic fat from previous studies into 
anterior mediastinal perithymic fat in this review, and left 
retrothyroid lobe, below thyroid isthmus, adjacent to left 
thyroid lobe, pretracheal tissue, left carotid sheath, cervical 
region and pretracheal infrathyroid fat into cervical region 
(pretracheal fat). Then the rate of ectopic thymic tissue at 
each anatomical location was calculated as number of cases 
with ectopic thymic tissue at the anatomical location divided 
by number of cases evaluating the presence of ectopic 
thymic tissue at this anatomical location.
Interestingly, in a prospective autopsy study, ectopic 
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after a two-stage resection (44). The researchers concluded 
that some anatomical locations with frequent presence 
of ectopic thymic tissue are hardly accessible to the first-
stage resection by “maximal” thymectomy. The inaccessible 
ectopic thymic tissue were frequently located along phrenic 
nerves with a rate of 32%, predominantly at the left side. 
This is in line with what Mulder described in 1986: “the left 
lobe tends to merge laterally with the fatty tissue contiguous 
with the phrenic nerve” (45). This is why we favor the left-
sided approach for robotic thymectomy in patients with 
nonthymomatous MG.
Clinical significance
Retrospective evidence has suggested a need for the 
resection of possible ectopic thymic tissue in mediastinal 
fat (19,30,46,47). Importantly, many retrospective studies 
have shown that the presence of ectopic thymic tissue is 
significantly associated with the poor outcome of MG 
patients undergoing thymectomy (Table 2) (24,26-28,32,37). 
Unfortunately, the outcome measures have varied 
considerably, thus it is difficult to perform an integrated 
analysis of the prognostic role of ectopic thymic tissue in 
patients with MG. 
In 1995, Ashour from King Khalid University hospital 
in Saudi Arabia first reported that the presence of ectopic 
thymic tissue is a significant predictor of poor outcome 
in patients with MG after transcervical-transsternal 
“maximal” thymectomy (24). The investigators from this 
institute defined complete remission as patients who were 
asymptomatic without medications. After a mean follow-
up period of 14.5 months (range, 4–72 months), complete 
remission was noted in 11 out of 23 patients (48%) without 










Figure 1 The rates of ectopic thymic tissue in common anatomic 
locations summarized from previous studies. 1, anterior mediastinal 
fat: 293 (33.2%); 2, pericardiophrenic angles: 120 (13.6%); 
3, aortopulmonary window: 92 (10.4%); 4, cervical region (pretracheal 
fat): 66 (7.5%); 5, lateral to phrenic nerves: 34 (3.9%); 6, aortocaval 
groove: 14 (1.6%); 7, behind innominate vein: 6 (0.7%).
Table 2 Summary of findings from articles evaluating the clinical significance of ETT in myasthenia gravis
Author [year] Country Surgical approach Total No.
No. with  
thymoma [%]




Ashour [1995] (24) Saudi Arabia Transcervical-transsternal ThX 38 0 [0] 15 [40] +
Mineo [2000] (25) Belgium Left-sided VATS 31 4 [13] 10 [32] −
Ozdemir [2002] (26) Turkey Median sternotomy 61 15 [25] 17 [28] +
Essa [2003] (27) Saudi Arabia Transcervical-transsternal ThX 30 0 [0] 10 [33] +
El-Medany [2003] (28) Saudi Arabia Transcervical-transsternal ThX 100 7 [7] 27 [27] +
Zielinski [2004] (30) Poland Median sternotomy 58 0 [0] 33 [57] −
Ponseti [2008] (32) Spain Median sternotomy 83 0 [0] 35 [42] +
Ambrogi [2012] (37) Italy Median sternotomy 106 0 [0] 51 [48] +
Marulli [2013] (39) Italy Left-sided RATS 100 8 [8] 26 [26] −
+ means that the presence of ectopic thymic tissue is associated with poor outcome of myasthenia gravis after thymectomy. − means 
that the presence of ectopic thymic tissue is not associated with the clinical outcome of myasthenia gravis after thymectomy. ThX, 
thymectomy; ETT, ectopic thymic tissue; VATS, video-assisted thoracoscopic surgery; RATS, robotic-assisted thoracoscopic surgery.
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with ectopic thymic tissue (24). Later on in 2003, Essa and 
colleagues from the same institute reported another series of 
30 children with MG who underwent thymectomy through 
the same surgical technique (27). One of 10 (10%) children 
with ectopic thymic tissue reached complete remission at a 
mean follow-up time of 53.5 months (range, 9–180 months), 
whereas 12 of 20 (60%) children without ectopic thymic 
tissue reached complete remission (27). In the same year, 
El-Medany and colleagues from the same center also 
reported the whole cohort of 100 myasthenic patients who 
underwent maximal thymectomy (28). Complete remission 
was observed in 5 out of 27 patients (18.5%) with ectopic 
thymic tissue and 31 out of 73 patients (42.5%) without 
ectopic thymic tissue after a mean follow-up period of 
7.6 years (range 8 to 180 months) (28). Therefore, the 
investigators concluded that patients without ectopic 
thymic tissue are more likely to reach complete remission in 
comparison to patients with ectopic thymic tissue. 
In 2003, Ozdemir and colleagues present the results of 
61 patients with MG who underwent extended thymectomy 
through a median sternotomy (26). In this retrospective 
study, remission was defined as no symptoms without 
medications and improvement was defined as no or fewer 
symptoms with the same or less medications. After a median 
follow-up time of 46 months (range, 12–81 months), 
improvement or remission was noted in 10 out of 17 (58.8%) 
patients with ectopic thymic tissue and 40 out of 44 (90.9%) 
patients without ectopic thymic tissue. Multivariate analysis 
by logistic regression model indicated that the presence of 
ectopic thymic tissue is an independent predictor on clinical 
outcome in MG patients undergoing extended thymectomy.
In 2008, Ponseti and colleagues researched on the influence 
of ectopic thymic tissue on the clinical outcome of 83 
seropositive generalized nonthymomatous MG patients who 
underwent transsternal thymectomy (32). In this retrospective 
report, thirty-five patients (42%) had ectopic thymic tissue. 
Clinical outcome was assessed according to Myasthenia 
Gravis Foundation of America (MGFA) post-intervention 
status. After a mean follow-up period of 88.4 months (range, 
20–144 months), 33 patients (69%) without ectopic thymic 
tissue obtained complete stable remission, whereas only 
nine patients (26%) with ectopic thymic tissue did so. The 
probability of complete stable remission at 5 years was 
65% in patients without ectopic thymic tissue and 26% in 
patients with ectopic thymic tissue. 
In 2012, Ambrogi and Mineo retrospectively reviewed 
the presence of ectopic thymic tissue in patients with 
seropositive nonthymomatous MGFA classification III MG 
who underwent extended thymectomy (37). Ectopic thymic 
tissue was found in 51 of 106 (48%) patients, of whom 
34 patients (67%) presented germinal centers (defined 
as active ectopic thymic tissue). Clinical outcome was 
assessed according to MGFA post-intervention status. In 96 
patients with a mean follow-up period of 160±91 months, 
ectopic thymic tissue and active ectopic thymic tissue were 
negatively associated with complete stable remission. Cox 
regression analysis demonstrated that the presence of active 
ectopic thymic tissue was the most significant negative 
predictor of complete stable remission. 
On the other hand, some studies found no influence 
of the presence of ectopic thymic tissue on the clinical 
outcome of patients with MG after thymectomy (Table 2) 
(25,30,39). According to Zielinski et al., however, this 
is possibly due to a complete resection of all fatty tissue 
in the mediastinum and the neck, which may result in a 
complete stable remission in patients with ectopic thymic 
tissue (30). Therefore, even though controversy still lies in 
the prognostic role of the presence of ectopic thymic tissue in 
patients with MG after thymectomy, results from the current 
literature have shed light on the importance of the removal 
of ectopic thymic tissue for the treatment of MG. From this 
point of view, the common locations of ectopic thymic tissue 
we summarized in this review might guide the resectional 
extent of thymectomy in the future clinical practice.
Discussion
It is likely that ectopic thymic tissue presents in more than 
half of the patients with MG and active ectopic thymic tissue 
presents in about 32% of them (Table 1). Although it can 
be found at any anatomical locations in both mediastinal 
and lower cervical fat, there seems to be some preferred 
sites. The distribution of active ectopic thymic tissue is still 
unclear. In addition, it takes a lot of time, money and efforts 
to address the ectopic thymic tissue and active ectopic thymic 
tissue, thus a well-designed prospective observational study 
should be of great value to provide high level of evidence. A 
comprehensive work-up from the MGTX group has been 
reported in detail, describing a perfect way of addressing 
the histopathology of thymectomy specimens (48,49). The 
role of ectopic thymic tissue is currently being investigated 
and the results are eagerly awaited. We highly recommend 
that each institute should reference this procedure in the 
histological workup of thymectomy specimen. 
Regarding the role of ectopic thymic tissue in patients 
with MG, it is possible that the persistent symptoms are 
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due to an “incomplete” resection or surgical intervention 
cannot influence the course of MG in this population. 
However, there is no effective way to locate ectopic thymic 
tissue preoperatively, which makes it impossible to address 
this hypothesis. The authors recommend further imaging 
research taking the reported common locations of ectopic 
thymic tissue as the regions of interest, thereby possibly 
improving the diagnostic accuracy of different imaging 
techniques. Besides, novel imaging techniques should be 
developed or introduced, such as multifrequency magnetic 
resonance elastography (50) and deep learning (51), in 
thymus imaging. Furthermore, a prediction model by the 
characteristics of patients or the biomarkers from peripheral 
blood might also be helpful to predict the presence of 
ectopic thymic tissue in patients with MG.
Although the clinical significance of ectopic thymic 
tissue is controversial, previous studies have shed light on 
its potential role in MG. First, the autoantibody is likely 
produced in active ectopic thymic tissues, e.g., B-cell 
follicles and germinal centers (52-55). Germinal centers 
were frequently found in ectopic thymic tissue, which was 
defined as active ectopic thymic tissue (37). Importantly, the 
presence of active ectopic thymic tissue is also significantly 
associated with poor outcome of patients with MG after 
thymectomy (37). Furthermore, some studies do support 
that changes in acetylcholine receptor antibody titers 
parallel with the clinical changes after thymectomy (56,57), 
although others do not (58,59). Second, “the more complete 
the resection, the better clinical outcome” has become an 
international consensus of thymectomy (60,61). On the 
other hand, ectopic thymic tissue was also found in more than 
a half of residual thymus after reoperations, which can relieve 
the persistent symptoms after the first partial resection (20). 
Third, even after exclusion of some subgroups such as 
congenital MG and MG seropositive for anti-muscle-specific 
kinase (MuSK) antibody (62,63), extended thymectomy 
cannot result in complete stable remission in all selected 
patients for surgery. This is possibly due to an incomplete 
resection of all ectopic thymic tissue (44). Furthermore, 
other factors such as timing of surgery may also influence 
the effectiveness of thymectomy even with the resection of 
all ectopic thymic tissue. Latest findings on the distribution 
of the germinal centers inside MG patients of the MGTX 
trial gave further insight on the association between clinical 
outcome and timing of surgery, which is consistent with the 
conclusion drawn by Sir Keynes in 1949 (64). Prof. Alexander 
Marx, the investigator of the thymus histology study for the 
MGTX trial, demonstrated (personal communication) that 
lymphocytes might migrate to bone marrow at a certain 
time after disease onset, which might diminish the influence 
of even most radical thymectomy on the improvement of 
MG. This might be another explanation for the remission 
rate being lower than 100% after extended thymectomy. All 
together, the retrospective evidence indicated that ectopic 
thymic tissue might be one of the factors that break the 
effectiveness of thymectomy in patients with MG. 
Different surgical approaches for thymectomy should 
attempt to remove all tissue in the mediastinum and neck 
that might harbor ectopic thymic tissue. It is possible that 
different surgical approaches can achieve complete resection 
with improved technology and instruments. Further studies 
may prove the equivalence of different surgical approaches 
by investigating the prevalence of ectopic thymic tissue 
harvested at different anatomical locations. However, some 
anatomical sites might be difficult to access. For example, 
the tissue in cervical region should be managed by gently 
grasping and bringing down to get a complete resection. 
Besides, the contralateral pleura should be opened to 
completely dissect the cardiophrenic tissue. However, as 
the therapeutic value of thymectomy continues to increase 
and might become relevant for more subgroups of MG, 
immunosuppressive drug therapy is, at the time of writing, still 
the backbone in the management of MG. Most patients with 
MG require, for a certain time, immunosuppressive medications 
to control symptoms and improve the quality of life. 
Conclusions
Ectopic thymic tissue is likely to present in more than a half 
of MG patients with the common locations being anterior 
mediastinal fat, pericardiophrenic angles, aortopulmonary 
window, cervical region (pretracheal fat) and lateral to 
phrenic nerves. So far, no imaging techniques can effectively 
locate the ectopic thymic tissue preoperatively. The clinical 
significance of ectopic thymic tissue is based on retrospective 
evidence and data on active ectopic thymic tissue are 
extremely limited, well-designed prospective observational 
studies are required to improve the evidence base, thereby 
improving the quality of care in patients with MG.
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